Zobrazeno 1 - 10
of 195
pro vyhledávání: '"VRC01"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ranajoy Mullick, Jyoti Sutar, Nitin Hingankar, Suprit Deshpande, Madhuri Thakar, Seema Sahay, Rajesh P. Ringe, Sampurna Mukhopadhyay, Ajit Patil, Shubhangi Bichare, Kailapuri G. Murugavel, Aylur K. Srikrishnan, Rajat Goyal, Devin Sok, Jayanta Bhattacharya
Publikováno v:
Retrovirology, Vol 18, Iss 1, Pp 1-13 (2021)
Abstract Background The potential use of the broadly neutralizing monoclonal antibodies (bnAbs) towards prophylaxis and treatment to HIV-1 is currently being explored. While a number of promising bnAbs have been discovered and a few of them have prog
Externí odkaz:
https://doaj.org/article/99653c24e0ee4fc79b2ce85aad8fba26
Autor:
Nneka Ugwu-Korie, Osbourne Quaye, Edward Wright, Sylvester Languon, Odame Agyapong, Emmanuel Broni, Yash Gupta, Prakasha Kempaiah, Samuel K. Kwofie
Publikováno v:
Molecules, Vol 28, Iss 2, p 474 (2023)
Broadly neutralizing antibodies (bNAbs) are potent in neutralizing a wide range of HIV strains. VRC01 is a CD4-binding-site (CD4-bs) class of bNAbs that binds to the conserved CD4-binding region of HIV-1 envelope (env) protein. Natural products that
Externí odkaz:
https://doaj.org/article/54c299fa218b4cbeae41fef4fbceed89
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
VRC01 is a broadly neutralizing antibody that targets the CD4 binding site of HIV-1 gp120. Passive administration of VRC01 in humans has assessed the safety and the effect on plasma viremia of this monoclonal antibody (mAb) in a phase 1 clinical tria
Externí odkaz:
https://doaj.org/article/4fea6d4ec5e34bc3ae62cceba36b7800
Autor:
Yunda Huang, Logashvari Naidoo, Lily Zhang, Lindsay N. Carpp, Erika Rudnicki, April Randhawa, Pedro Gonzales, Adrian McDermott, Julie Ledgerwood, Margarita M.Gomez Lorenzo, David Burns, Allan DeCamp, Michal Juraska, John Mascola, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Lawrence Corey, Philip Andrew, Shelly Karuna, Peter B. Gilbert, Kathryn Mngadi, Erica Lazarus
Publikováno v:
EBioMedicine, Vol 64, Iss , Pp 103203- (2021)
The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland.
Externí odkaz:
https://doaj.org/article/46ca6747a177430f915ba48c115dcd47
Autor:
Young D. Kwon, Mangaiarkarasi Asokan, Jason Gorman, Baoshan Zhang, Qingbo Liu, Mark K. Louder, Bob C. Lin, Krisha McKee, Amarendra Pegu, Raffaello Verardi, Eun Sung Yang, VRC Production Program, Kevin Carlton, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola, Peter D. Kwong
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Passive transfer of broadly neutralizing antibodies is showing promise in the treatment and prevention of HIV-1. One class of antibodies, the VRC01 class, appears especially promising. To improve VRC01-class antibodies, we combined structure-based de
Externí odkaz:
https://doaj.org/article/fd7ff32ab1e546deaa0798bcdf196936
Autor:
Yunda Huang, Shelly Karuna, Lindsay N. Carpp, Daniel Reeves, Amarendra Pegu, Kelly Seaton, Kenneth Mayer, Joshua Schiffer, John Mascola, Peter B. Gilbert
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 9, Pp 2116-2127 (2018)
The Antibody Mediated Prevention trials are assessing whether intravenously-administered VRC01 (10 mg/kg or 30 mg/kg vs placebo) can prevent HIV infection. In a modeling exercise, we used two models to predict the overall prevention efficacy (PE) of
Externí odkaz:
https://doaj.org/article/14375d417ee24111baa289d8eaaa14dd
Autor:
Alexander Falkenhagen, Sadhna Joshi
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 7, Iss C, Pp 387-395 (2017)
HIV entry into target cells is a highly sequential and time-sensitive process. In recent years, potent HIV Env-targeting antibodies, such as VRC01, have been identified. However, antibodies bind only to a single epitope, and mutations that confer res
Externí odkaz:
https://doaj.org/article/23a8eef9e49846afbe082b2d607f65d6
Autor:
Christina Yacoob, Marie Pancera, Vladimir Vigdorovich, Brian G. Oliver, Jolene A. Glenn, Junli Feng, D. Noah Sather, Andrew T. McGuire, Leonidas Stamatatos
Publikováno v:
Cell Reports, Vol 17, Iss 6, Pp 1560-1570 (2016)
Elicitation of broadly neutralizing antibodies remains a long-standing goal of HIV vaccine research. Although such antibodies can arise during HIV-1 infection, gaps in our knowledge of their germline, pre-immune precursor forms, as well as on their i
Externí odkaz:
https://doaj.org/article/89b0691fe5784d43ad3379ed62d6fd1e
Autor:
Andrew J Borst, Connor E Weidle, Matthew D Gray, Brandon Frenz, Joost Snijder, M Gordon Joyce, Ivelin S Georgiev, Guillaume BE Stewart-Jones, Peter D Kwong, Andrew T McGuire, Frank DiMaio, Leonidas Stamatatos, Marie Pancera, David Veesler
Publikováno v:
eLife, Vol 7 (2018)
VRC01 broadly neutralizing antibodies (bnAbs) target the CD4-binding site (CD4BS) of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env). Unlike mature antibodies, corresponding VRC01 germline precursors poorly bind to Env. Immunog
Externí odkaz:
https://doaj.org/article/a11468bd4dce41cdae2356acea7e4869